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When rat pancreatic islets were incubated with 1Om8 M arginine vasopressin in the presence of 15 mM glucose there was 
a pronounced inhibition of insulin release in comparison with controls. This inhibitory effect appeared to be specific for 
vasopressin since it was antagonised by vasopressin antibody. Moreover, pertussis toxin (100 ng/ml) reversed the inhibi- 
tion of insulin release due to vasopressin, indicating the possible involvement of a guanyl-nucleotide regulatory protein 
in the inhibitory effect. Nevertheless, IO-* M vasopressin increased islet concentrations of cyclic AMP even under condi- 
tions where insulin release was decreased. 
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1. INTRODUCTION 
Vasopressin exhibits a variety of metabolic ef- 
fects in addition to its well known antidiuretic and 
vasopressor activities. Among cells affected are 
hepatocytes, adrenal glomerulosa cells and human 
platelets. Tissue vasopressin receptors have also 
been extensively studied, and it has been suggested 
that there is more than one type of receptor involv- 
ed in the mode of action of this hormone. There is 
also much evidence to implicate a guanyl- 
nucleotide regulatory protein in the action of 
vasopressin [ 1,2]. 
There has, however, been uncertainty concern- 
ing the effect of vasopressin on the islets of 
Langerhans. There are contradictory reports as to 
how vasopressin affects insulin release either in 
vivo [3-51, or in vitro 161. 
We have re-investigated how vasopressin affects 
islet function in vitro. Our present study on the 
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islets reveals that vasopressin in physiological con- 
centrations persistently inhibits insulin secretion in 
the presence of stimulatory concentration of 
glucose. We have further investigated how 
vasopressin may affect cyclic AMP levels in islets 
and whether the inhibitory response to vasopressin 
is reversed by treatment with pertussis toxin. 
2. MATERIALS AND METHODS 
Islets of Langerhans were isolated from male Sprague- 
Dawley rats [7] (body wt 150-200 g). Ten islets were incubated 
with either 5 or 15 mM glucose with or without 
[Arg’lvasopressin (Sigma) at a concentration of lo-* M in ox- 
ygenated bicarbonate buffer containing 0.1% bovine serum 
albumin. After incubation for I h at 37°C in a shaking water- 
bath, insulin was measured in the incubation medium by 
radioimmunoassay (RIA) [8]. 
[Arg*]Vasopressin antibody (Biogenesis), at a dilution 1: 10 
of the commercial preparation, was used with vasopressin at a 
concentration of 0.5 x lo-” M. The hormone and its antibody 
were incubated together for 1 h then added to the islets and in- 
cubated for a further hour. After the incubation period, insulin 
secretion was measured by RIA. Pertussis toxin (kindly donated 
by Dr Irons of Porton International) was incubated with the 
islets overnight at a concentration of 100 ng/ml in tissue culture 
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medium RPM1 1640 and 5 mM glucose. The islets were then 
washed with fresh bicarbonate buffer and incubated with 
[Arg’]vasopressin for 1 h. Cyclic AMP was measured by im- 
munoassay 191 using a kit obtained from New England Nuclear. 
In the assay 15 islets were incubated in each tube for 10 min 
with IO-* M [Args]vasopressin. 
3. RESULTS 
In the present study vasopressin was incubated 
with the islets of Langerhans at 2 different concen- 
trations of glucose (table 1). The insulin response 
to 15 mM glucose was inhibited by vasopressin but 
this was not so at a basal glucose concentration 
(5 mM). The inhibitory action of vasopressin on 
insulin secretion seems to be specific for the 
vasopressin molecule. This is also shown in table 1, 
where the results of incubating [Arg*]vasopressin 
with islets in the presence of vasopressin antibody 
are shown. The inhibitory effects are abolished. 
Furthermore, when the islets were incubated over- 
Table 1 
Effect of [Arg’lvasopressin on islet insulin release with and 
without vasopressin antibody 
Additions to incubation medium Insulin release 
(pg/islet 
per min) 
Expt 1 
glucose (5 mM) 1.80 i 0.19 
(10) a 
glucose (5 mM) + vasopressin (10m8 M) 
glucose (15 mM) 
1.70 t 0.13 
( 6) 
6.32 r 0.06 
(11) b 
glucose (15 mM) + vasopressin (10m8 M) 3.65 f 0.25 
(10) c 
Expt 2 
glucose (5 mM) 
glucose (15 mM) 
0.91 * 0.09 
(5)d 
2.70 rt 0.22 
( 5) e 
glucose (15 mM) + vasopressin (lo-” M) 1.59 * 0.10 
( 5) f 
glucose (15 mM) + vasopressin (lo-” M) 
+ vasopressin antibody 2.67 * 0.16 
( 5) g 
For differences between a and b; b and c, d and e, e and f and 
f, and g, p < 0.001. Isolated rat islets were incubated as shown. 
The amount of insulin secreted during the incubation period 
was determined by RIA. Values given are means f SE. Number 
of observations are shown in parentheses 
Table 2 
Effect of pertussis toxin treatment on [Arg*]vasopressin 
inhibition of insulin secretion 
Additions to 
incubation medium 
Insulin secretion 
@g/islet per min) 
Control Toxin treated 
(100 ng/ml) 
5 mM glucose 2.92 f 0.47 3.56 f 0.43 
(5) (5) 
5 mM glucose + lo-’ M 
vasopressin 2.06 f 0.35 4.14 f 0.74 
(5) (5) 
15 mM glucose 21.98 f 0.97 25.08 f 0.68 
(5) (5) a 
15 mM glucose + 10e8 M 
vasopressin 12.64 f 0.85 23.05 f 1.26 
(5) (5) b 
For differences between control and toxin-treated islets (a) p < 
0.02, (b) p < 0.001. For other differences between these two 
groups, p > 0.05. Isolated rat pancreatic islets were 
preincubated with pertussis toxin overnight (100 ng/ml) then 
washed and incubated as in text for 1 h. Insulin secreted during 
incubation period was determined by RIA. Values are means f 
SE. Number of observations are shown in parentheses 
night with 100 ng/ml pertussis toxin (table 2) and 
then incubated with vasopressin, the inhibitory ef- 
fect of vasopressin was reversed even in the 
presence of high concentrations of glucose. When 
pertussis toxin is incubated with islets alone, there 
is a small stimulation of insulin release above the 
control values. Although vasopressin inhibited in- 
sulin release, it increased cyclic AMP concentra- 
tion in islets (table 3), at both 5 and 15 mM 
gIucose. 
Table 3 
Cyclic AMP levels in [Arg’lvasopressin-treated rat islets 
Additions to Cyclic AMP 
incubation medium (fmol/islet per min) 
5 mM glucose (control) 10.72 f 0.65 (5) 
5 mM glucose and low8 M vasopressin 22.50 f 1.10 (5) a 
15 mM glucose (control) 15.82 rt 1.80 (5) 
15 mM glucose and 10e8 M vasopressin 21.98 f 0.81 (5) b 
For differences between appropriate controls and values a and 
b, p c 0.02. Groups of 15 islets/tube were incubated for 10 min 
as shown, then taken for RIA to measure cyclic AMP levels. 
Values are means f SE. Number of observations are shown in 
parentheses 
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4. DISCUSSION 
The inhibitory effect of [Arg’]vasopressin on 
glucose-stimulated insulin release was unexpected. 
In tissues such as liver, vasopressin produces a rise 
in cytosolic calcium. If vasopressin had behaved 
this way in islets, then the rise in calcium would be 
expected to increase insulin release. 
However, other studies in vivo have also sug- 
gested that vasopressin may inhibit insulin release. 
Thus, in dogs, it has been shown that vasopressin 
inhibits the rise in plasma insulin caused by ox- 
ytocin [4]. Earlier experiments on the effects of 
vasopressin on islets in vitro were inconclusive 161. 
Moreover, the effect of vasopressin is seen at 
physiological concentrations (0.5 x lo-” M). The 
inhibitory action of vasopressin on insulin release 
at this concentration was reversed by adding a 
specific [Arg’]vasopressin antibody to the 
medium. In addition, a similar inhibition of 
glucose-stimulated release was shown in the 
presence of [Lys*]vasopressin (not shown). This 
adds weight to the idea that the inhibitory effect is 
a feature of the vasopressin molecule. 
However, the mechanism of inhibition is uncer- 
tain. Since it is reversed by pertussis toxin, 
vasopressin may be exercising its inhibitory effect 
through a guanyl-nucleotide regulatory protein. 
Several other reports indicate that vasopressin ap- 
pears to exert its effects by this means [lo,1 11. 
Despite its inhibitory effect on insulin release, 
[Arg’lvasopressin was able to increase cyclic AMP 
accumulation in islets. There have been conflicting 
reports about the effect of vasopressin on cyclic 
AMP accumulation in various tissues. Thus, in 
liver, vasopressin alone had no effect on cyclic 
AMP levels [12,13]. By contrast, it has recently 
been shown that vasopressin was able to increase 
cyclic AMP in smooth muscle cell culture [14]. 
Islets of Langerhans appear to resemble smooth 
muscle in this respect. 
It is generally supposed that there are two types 
of receptors by which vasopressin is functional in 
tissues. These have been designated VI and VZ type 
receptors [15]. The VZ receptor operates through 
adenylate cyclase and the Vl receptor is assumed to 
act through the phosphatidylinositol system in- 
volving changes in cytosolic Cazf concentrations 
[ 16-181. Our results suggest that the VZ type of 
receptor may be operative in islets. Presumably to 
exercise its inhibitory effect, vasopressin is not 
associated with the classical VI receptor, already 
described in other tissues. 
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